These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11156542)

  • 41. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
    Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
    Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Light therapy (with UVA-1) for SLE patients: is it a good or bad idea?
    Pavel S
    Rheumatology (Oxford); 2006 Jun; 45(6):653-5. PubMed ID: 16522677
    [No Abstract]   [Full Text] [Related]  

  • 44. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
    Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2013 Mar; 40(3):265-72. PubMed ID: 23204220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus.
    Szegedi A; Simics E; Aleksza M; Horkay I; Gaál K; Sipka S; Hunyadi J; Kiss E
    Rheumatology (Oxford); 2005 Jul; 44(7):925-31. PubMed ID: 15827034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
    Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of connective tissue disorder-related acral syndromes using UVA-1 phototherapy. An open study of 11 cases].
    Comte C; Bessis D; Picot E; Peyron JL; Guillot B; Dereure O
    Ann Dermatol Venereol; 2009 Apr; 136(4):323-9. PubMed ID: 19361698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two systemic lupus erythematosus (SLE) global disease activity indexes--the SLE Disease Activity Index and the Systemic Lupus Activity Measure--demonstrate different correlations with activation of peripheral blood CD4+ T cells.
    Daca A; Czuszyńska Z; Smoleńska Z; Zdrojewski Z; Witkowski JM; Bryl E
    Hum Immunol; 2011 Dec; 72(12):1160-7. PubMed ID: 21906646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.
    Mackworth-Young CG; David J; Morgan SH; Hughes GR
    Ann Rheum Dis; 1988 Jun; 47(6):496-502. PubMed ID: 3289511
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus.
    Wright SA; O'Prey FM; McHenry MT; Leahey WJ; Devine AB; Duffy EM; Johnston DG; Finch MB; Bell AL; McVeigh GE
    Ann Rheum Dis; 2008 Jun; 67(6):841-8. PubMed ID: 17875549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.
    Grabar S; Groh M; Bahuaud M; Le Guern V; Costedoat-Chalumeau N; Mathian A; Hanslik T; Guillevin L; Batteux F; Launay O;
    Vaccine; 2017 Sep; 35(37):4877-4885. PubMed ID: 28784280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Randomized, Double-blind, Placebo-controlled Clinical Trial Examining the Effects of Green Tea Extract on Systemic Lupus Erythematosus Disease Activity and Quality of Life.
    Shamekhi Z; Amani R; Habibagahi Z; Namjoyan F; Ghadiri A; Saki Malehi A
    Phytother Res; 2017 Jul; 31(7):1063-1071. PubMed ID: 28585735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.
    Dall'Era M; Chakravarty E; Wallace D; Genovese M; Weisman M; Kavanaugh A; Kalunian K; Dhar P; Vincent E; Pena-Rossi C; Wofsy D
    Arthritis Rheum; 2007 Dec; 56(12):4142-50. PubMed ID: 18050206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
    Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
    J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.